carbamylhydrazine has been researched along with Parkinson Disease in 2 studies
carbamylhydrazine: RN given refers to parent cpd
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Palfreyman, MG | 1 |
| McDonald, IA | 1 |
| Bey, P | 1 |
| Danzin, C | 1 |
| Zreika, M | 1 |
| Cremer, G | 1 |
| Maruyama, W | 1 |
| Naoi, M | 1 |
| Kasamatsu, T | 1 |
| Hashizume, Y | 1 |
| Takahashi, T | 1 |
| Kohda, K | 1 |
| Dostert, P | 1 |
1 trial available for carbamylhydrazine and Parkinson Disease
| Article | Year |
|---|---|
Haloallylamine inhibitors of MAO and SSAO and their therapeutic potential.
Topics: Allyl Compounds; Amine Oxidase (Copper-Containing); Animals; Butylamines; Drug Evaluation; Humans; M | 1994 |
1 other study available for carbamylhydrazine and Parkinson Disease
| Article | Year |
|---|---|
An endogenous dopaminergic neurotoxin, N-methyl-(R)-salsolinol, induces DNA damage in human dopaminergic neuroblastoma SH-SY5Y cells.
Topics: Antioxidants; Apoptosis; Carcinogens; Catalase; Cycloheximide; DNA Damage; Dopamine; Free Radicals; | 1997 |